TP53 and neoplasm: Additionally, we show that mutant p53, which is the key driver of the majority (>70%) of EACs, partners with GRAIL1 to influence the tumor cell secretome, enhancing the release of ISG15 by tumor cells (Figure 8), a paracrine factor reported to reprogram the TME.